title: Expression of MECOM is associated with unfavorable prognosis in glioblastoma multiforme.
abstract: BACKGROUND
  MDS1 and EVI1 complex locus protein EVI1 (MECOM) is an oncogenic transcription factor in several kinds of cancers. However, the clinical significance of MECOM in glioblastoma multiforme (GBM) has not been well elucidated.
  
  
  METHODS
  Our study enrolled 86 resected samples of GBM in three medical centers. We detected the expression of MECOM in all the 86 samples by immunohistochemistry and compared the difference of MECOM mRNA between tumor tissues and adjacent tissues with real-time polymerase chain reaction. With immunoblotting, we detected the MECOM expression in different GBM cell lines. Moreover, we analyzed the correlation between MECOM expression and clinicopathologic factors with chi-square test, and evaluated the prognostic value of MECOM with univariate and multivariate analysis.
  
  
  RESULTS
  In GBM tissue, the percentage of MECOM high expression is 41.9% (36/86). The mRNA of MECOM in tumor tissues is remarkably higher than that in adjacent tissues, indicating the oncogenic role of MECOM in GBM. MECOM exists in all the detected cell lines with different abundance. Moreover, MECOM is correlated with poorer overall survival rate (P=0.033) and can be identified as an independent prognostic factor in GBM (P=0.042).
  
  
  CONCLUSIONS
  MECOM could be considered as an independent prognostic factor in GBM, predicting it as a potential and promising molecular drug target.
authors.affiliation: Department of Neurology, Yidu Central Hospital of Weifang City.
authors.forename: Aiwu
authors.initials: A
authors.lastname: Hou
authors.affiliation: Department of Neurology, Yidu Central Hospital of Weifang City.
authors.forename: Lizhen
authors.initials: L
authors.lastname: Zhao
authors.affiliation: Department of Orthopedics, People's Hospital of Qingzhou City.
authors.forename: Fuzhen
authors.initials: F
authors.lastname: Zhao
authors.affiliation: Department of Psychiatrics, People's Third Hospital of Weifang City, Weifang.
authors.forename: Weiliang
authors.initials: W
authors.lastname: Wang
authors.affiliation: Department of Neurology, Yidu Central Hospital of Weifang City.
authors.forename: Jianyi
authors.initials: J
authors.lastname: Niu
authors.affiliation: Department of Neurology, Yidu Central Hospital of Weifang City.
authors.forename: Bingxuan
authors.initials: B
authors.lastname: Li
authors.affiliation: Department of Neurology, Yidu Central Hospital of Weifang City.
authors.forename: Zhongjin
authors.initials: Z
authors.lastname: Zhou
authors.affiliation: Department of Medical Oncology, Shandong Cancer Hospital and Institute, Shandong Academy of Medical Sciences.
authors.forename: Dongyuan
authors.initials: D
authors.lastname: Zhu
keywords: MECOM; glioblastoma multiforme; prognosis; progression
references.citation: EMBO J. 2000 Jun 15;19(12):2958-68
references.pmid: 10856240
references.citation: Tumour Biol. 2014 Sep;35(9):9255-62
references.pmid: 24935473
references.citation: J Biol Chem. 2005 Sep 2;280(35):30712-22
references.pmid: 16006653
references.citation: Blood. 2015 Jan 1;125(1):140-3
references.pmid: 25331116
references.citation: Blood. 2011 Mar 31;117(13):3617-28
references.pmid: 21289308
references.citation: Cell. 1988 Sep 9;54(6):831-40
references.pmid: 2842066
references.citation: Oncogene. 2009 Dec 10;28(49):4364-74
references.pmid: 19767769
references.citation: Nature. 2008 Oct 23;455(7216):1061-8
references.pmid: 18772890
references.citation: Metabolism. 2015 Mar;64(3 Suppl 1):S22-7
references.pmid: 25468141
references.citation: Biochem Pharmacol. 2013 Feb 15;85(4):478-85
references.pmid: 23159669
references.citation: JAMA. 2013 Nov 6;310(17):1842-50
references.pmid: 24193082
references.citation: Cell Biochem Funct. 2010 Jul;28(5):343-51
references.pmid: 20535838
references.citation: CA Cancer J Clin. 2010 May-Jun;60(3):166-93
references.pmid: 20445000
references.citation: Lancet Oncol. 2014 Aug;15(9):e395-403
references.pmid: 25079102
references.citation: EMBO J. 2005 Jun 1;24(11):1976-87
references.pmid: 15889140
references.citation: Mol Oncol. 2013 Jun;7(3):647-68
references.pmid: 23517670